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Hepatocyte Growth Factor/
c-Met Signaling Is Required
for b-Cell Regeneration
Hepatocyte growth factor (HGF) is a mitogen
required for b-cell replication during pregnancy. To
determine whether HGF/c-Met signaling is required
for b-cell regeneration, we characterized mice with
pancreatic deletion of the HGF receptor, c-Met
(PancMet KO mice), in two models of reduced b-cell
mass and regeneration: multiple low-dose
streptozotocin (MLDS) and partial pancreatectomy
(Ppx). We also analyzed whether HGF administration
could accelerate b-cell regeneration in wild-type
(WT) mice after Ppx. Mouse islets obtained 7 days
post-Ppx displayed signiﬁcantly increased c-Met,
suggesting a potential role for HGF/c-Met in b-cell
proliferation in situations of reduced b-cell mass.
Indeed, adult PancMet KO mice displayed markedly
reduced b-cell replication compared with WT mice 7
days post-Ppx. Similarly, b-cell proliferation was
decreased in PancMet KO mice in the MLDS mouse
model. The decrease in b-cell proliferation post-Ppx
correlated with a striking decrease in D-cyclin levels.
Importantly, PancMet KO mice showed signiﬁcantly
diminished b-cell mass, decreased glucose tol-
erance, and impaired insulin secretion compared
with WT mice 28 days post-Ppx. Conversely, HGF
administration in WT Ppx mice further accelerated
b-cell regeneration. These results indicate that
HGF/c-Met signaling is critical for b-cell proliferation
in situations of diminished b-cell mass and suggest
that activation of this pathway can enhance b-cell
regeneration.
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Deﬁciency of functional b-cells ultimately leads to the
development of diabetes. A potential future therapeutic
approach to treat diabetes is to induce b-cell re-
generation, but this requires deciphering the molecular
mechanisms that control b-cell growth. In adult mice,
b-cell replication is one of the main mechanisms to form
new b-cells (1), but in basal conditions their proliferative
capacity is very limited and further decreases with age
(2). Several conditions, however, are known to stimulate
b-cell replication including pregnancy, obesity, partial
pancreatectomy (Ppx), and growth factor overexpression
(3). Among these growth factors, we have shown that
hepatocyte growth factor (HGF) overexpression increases
b-cell replication, mass, and function in transgenic mice
(4,5). Importantly, HGF regulates regeneration of
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multiple organs after injury (6–8). However, whether
HGF plays a role in b-cell regeneration is unknown.
HGF binds with high afﬁnity to and induces the di-
merization of its tyrosine kinase receptor, c-Met (8).
Both HGF and c-Met are expressed in the endocrine and
nonendocrine pancreas, but conditional ablation of c-Met
in adult mouse pancreas does not alter b-cell growth or
function under basal conditions (9). However, we re-
cently showed that pancreatic c-Met deﬁciency accel-
erates the onset of diabetes in a mouse model of multiple
low-dose streptozotocin (MLDS) administration (9).
Moreover, HGF is also required for maternal b-cell pro-
liferation during pregnancy (10). Taken together, these
studies indicate that HGF/c-Met signaling is required for
b-cell adaptation to inﬂammatory and metabolic sit-
uations. They also suggest that HGF/c-Met signaling
might participate in the regenerative response of b-cells
after b-cell ablation. To address this issue, we analyzed
b-cell regeneration in PancMet KO mice under situations
of Ppx and MLDS treatment. Here, we report that c-Met
is critically important for complete b-cell regeneration
and that HGF administration into normal mice further
accelerates b-cell regeneration post-Ppx. These observa-
tions underscore a therapeutic opportunity for the HGF/
c-Met signaling pathway in diabetes.
RESEARCH DESIGN AND METHODS
Generation of Conditional KO Mice With Pancreas
Deletion of c-Met
PancMet KO mice were generated as previously described
(9). Male mice (8–10 weeks old) were used in these studies.
All studies were performed with the approval of, and in
accordance with, guidelines established by the Icahn School
of Medicine at Mount Sinai and the University of Pitts-
burgh institutional animal care and use committees.
MLDS-Induced Diabetes and Ppx Mouse Models
In the MLDS model, mice were injected with streptozo-
tocin (40 mg/kg i.p.) for ﬁve consecutive days (9). For the
Ppx model, the splenic portion of the pancreas was sur-
gically removed (;50–60% pancreatectomy) (11–13).
Sham (SH) operation was performed by opening the
abdomen while leaving the pancreas intact.
HGF Administration
Human recombinant HGF (Fitzgerald Industries In-
ternational, Acton, MA) was administered in conjunction
with dextran sulfate (DS), since DS enhances the effect
and stability of HGF (14). DS (200 mg/mouse) was dis-
solved in saline and mixed with HGF (20 mg/mouse), and
the mixture was injected intraperitoneally daily after
Ppx. Control SH or Ppx mice were injected with an
identical volume of saline.
Glucose Homeostasis
Blood was analyzed for glucose by a portable glucometer
and plasma insulin by radioimmunoassay (Millipore,
Bedford, MA) (4).
Immunohistochemistry
b-Cell mass and islet number were measured in four
insulin-stained pancreas sections per mouse using
ImageJ (National Institutes of Health, Bethesda, MD)
(9,10). BrdU incorporation in b-cells was measured in
pancreatic sections from mice injected intraperitoneally
with BrdU (Amersham, Piscataway, NJ), killed 6 h later,
and stained for insulin and BrdU (10). Sections were also
stained for Ki67, phospho–histone-H3 (pHH3), and in-
sulin (15). At least 2,000 b-cells/pancreas were counted.
Figure 1—Analysis of HGF and c-Met expression in islets from
SH-operated or Ppx WT mice at 7 days postsurgery. A: Real-time
PCR analysis of HGF and c-Met mRNA expression in total RNA
extracted from islets obtained from WT mice 7 days after surgery.
Results are means 6 SEM of SH-operated (n = 4) and Ppx (n = 3)
mice. P < 0.05 vs. SH-operated mouse islets. Actin was used as
a housekeeping gene. B: Western blot analysis of c-Met and HGF
expression in protein extracts of islets isolated from WT mice 7
days after surgery. Results are means 6 SEM of SH-operated (n =
4) and Ppx (n = 4) mice. P < 0.05 vs. SH-operated mouse islets.
Inset: Representative Western blot. Tubulin was used as house-
keeping protein. 2^(2ddCt) = 2(2delta delta Cycle threshold).
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Figure 2—b-Cell proliferation in Ppx and MLDS-treated PancMet KO mice. A–D: Representative photomicrographs of SH-operated (A
and B) and Ppx (C and D) WT (A and C) and PancMet KO (B and D) mouse pancreatic sections obtained at 7 days postsurgery and stained
for insulin (green) and Ki67 (red). Arrows indicate Ki67-positive b-cell nuclei. Magniﬁcation of the images is 3630. E–G: Quantiﬁcation of
the percentage of Ki67-positive (E), BrdU-positive (F ), and pHH3-positive (G) b-cells in SH-operated (n = 3) and Ppx (n = 7) WT and
PancMet KO (n = 3 and n = 9, respectively) mice 7 days after surgery. Results are means 6 SEM. *P < 0.05 vs. their corresponding SH-
operated mice; #P < 0.05 vs. Ppx-WT mice. Values are not signiﬁcantly different except where indicated. H and I: Representative
photomicrographs of MLDS-treated WT (H) and PancMet KO (I) mouse pancreatic sections obtained at 20 days post-MLDS treatment and
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Islet Isolation and mRNA Expression Analysis
Mouse islets were isolated after collagenase P injection
through the pancreatic duct (4). Analysis of c-Met and
HGF mRNA expression in isolated islets was performed
by real-time PCR using speciﬁc primers and conditions
previously described (9,10).
Glucose-Stimulated Insulin Secretion
Insulin release from 10–15 islets isolated from Ppx mice
at 25 days postsurgery was measured after incubation
with 2.8 or 22.2 mmol/L glucose for 30 min (12). Insulin
secretion is expressed as percentage of total islet insulin
content.
Western Blot Analysis
Mouse islet extracts were analyzed by Western blotting
with antibodies against c-Met and cyclin-dependent
kinase-4 (cdk-4) (Santa Cruz Biotechnology, Santa
Cruz, CA), tubulin and HGF (Calbiochem, La Jolla, CA),
and cyclin D1 and D2 (Thermo Fisher Scientiﬁc, Fre-
mont, CA). After several washes, blots were incubated
with peroxidase-conjugated secondary antibodies fol-
lowed by chemiluminescence detection (9,10).
Statistical Analysis
The data are presented as means 6 SE. Statistical anal-
ysis was performed using unpaired two-tailed Student
t test. P , 0.05 was considered statistically signiﬁcant.
RESULTS
c-Met Expression Increases in Mouse Islets After Ppx
Analysis of c-Met expression in mouse islets obtained
7 days (7 days) after Ppx indicate that both c-Met mRNA
(Fig. 1A) and protein (Fig. 1B) are increased in this model
of b-cell regeneration. On the other hand, HGF mRNA
and protein expression remained unchanged in these
islets (Fig. 1). Collectively, these data and previous data
in the MLDS model (9) suggest that reduction of b-cell
mass is associated with an increase in c-Met expression
in the remnant islets.
b-Cell Proliferation Does Not Increase in PancMet KO
Mice After Both Ppx and MLDS Treatment
Since islet c-Met is upregulated after Ppx and MLDS
treatments (Fig. 1) (9) and HGF increases b-cell pro-
liferation (4), we sought to address the importance of
c-Met in b-cell replication in these two mouse models of
decreased b-cell mass. Pancreatic mass removed after
Ppx was not different in both types of mice (Supple-
mentary Fig. 1A). Body weight was not signiﬁcantly dif-
ferent among these mice postsurgery (Supplementary
Fig. 1B). As expected, b-cell mass was signiﬁcantly di-
minished 7 days post-Ppx compared with SH-operated
mice, but it was not signiﬁcantly different between wild-
type (WT) and PancMet KO mice in either surgical group
(Supplementary Fig. 1C). In contrast, as shown in the
representative images (Fig. 2A–D) and the corresponding
quantitation (Fig. 2E–G), the number of proliferating
b-cells (Ki67-, pHH3-, and BrdU-positive) was markedly
and signiﬁcantly decreased in PancMet KO mice com-
pared with WT littermates 7 days post-Ppx. No evident
alterations in vimentin staining were observed in pan-
creatic sections of WT and PancMet KO mice post-Ppx
(not shown), suggesting that changes in epithelial-to-
mesenchymal transition might not be involved in the
proliferative changes observed in PancMet KO mice after
Ppx.
The number of BrdU-positive b-cells was also signiﬁ-
cantly decreased in PancMet KO mice 20 days post-
MLDS treatment (Fig. 2H–J). These results indicate that
intact HGF/c-Met signaling is required for b-cell pro-
liferation in situations of diminished b-cell mass ac-
companied by islet inﬂammation and diabetes (MLDS
model) (9) or without islet inﬂammation and normal
glucose homeostasis (Ppx model) (Supplementary Fig. 1D
and E).
Ppx-Induced Upregulation of D Cyclins Is Diminished
in PancMet KO Mouse Islets
D cyclins are upregulated in rodent islets when maximal
proliferation occurs after Ppx (11,16). To determine
whether the decrease in b-cell proliferation in PancMet
KO mice after Ppx was associated with changes in G1/S
transition activators, we analyzed D-cyclin and cdk-4
levels in PancMet KO and WT mouse islets 7 days post-
Ppx. PancMet KO islets post-Ppx displayed a remarkable
and signiﬁcant decrease in cyclins D1 and D2, with no
alteration in cdk-4 (Fig. 2K–N), suggesting an association
between lower D cyclins and diminished b-cell replication
in PancMet KO mice post-Ppx.
PancMet KO Mice Have Incomplete b-Cell Mass
Regeneration and Diminished Glucose Tolerance
We assessed the impact of HGF/c-Met signaling on b-cell
regeneration in PancMet KO and WT mice at 28 days
stained for insulin (green) and BrdU (red). Arrows indicate BrdU-positive b-cell nuclei. Magniﬁcation of the images is3630. J: Quantiﬁcation
of the percentage of BrdU-positive b-cells in untreated (n = 5) and MLDS-treated (n = 10) WT and PancMet KO (n = 5 and n = 5, re-
spectively) mice 20 days after treatment. Results are means 6 SEM. *P < 0.05 vs. corresponding untreated mice; #P < 0.05 vs. MLDS-WT
mice. Values are not signiﬁcantly different except where indicated. K: Representative Western blot displaying cyclin D1, D2, cdk-4, and
tubulin expression in protein extracts from SH-operated or Ppx PancMet KO and WT islets obtained at 7 days postsurgery. L–N: Densi-
tometric quantitation of cyclin D1 (L), cyclin D2 (M), and cdk-4 (N) in ﬁve Western blots performed with ﬁve different protein extracts per
condition. Results are means 6 SEM. *P < 0.05 vs. SH-operated WT or PancMet KO mice; #P < 0.05 vs. Ppx WT mice. Values are not
signiﬁcantly different except where indicated. Ins, insulin.
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after Ppx. b-Cell mass was increased in WT mice post-
Ppx, reaching similar levels to SH-operated mice (Fig.
3A). Importantly, b-cell mass in PancMet KO mice was
signiﬁcantly decreased post-Ppx compared with WT mice
and SH-operated mice (Fig. 3A), indicating incomplete
b-cell regeneration. Islet number was not different be-
tween PancMet KO and WT littermates at 28 days post-
Ppx (not shown), suggesting that the early decrease in
b-cell proliferation was potentially responsible for the
incomplete b-cell regeneration in c-Met–deﬁcient mice.
Furthermore, PancMet KO mice displayed decreased
glucose tolerance at 25 days post-Ppx, suggesting that
the incomplete b-cell mass and perhaps defective insulin
secretion might have an impact on glucose homeostasis
in c-Met–deﬁcient mice (Fig. 3B and C). Indeed, glucose-
stimulated insulin secretion (GSIS) is decreased in iso-
lated islets from PancMet KO mice 25 days post-Ppx
compared with WT mice (Fig. 3D). Taken together, these
results indicate that HGF/c-Met signaling is required for
full b-cell mass recovery and normal GSIS and glucose
homeostasis in a model of surgically reduced b-cell mass.
HGF Administration Further Enhances b-Cell
Proliferation After Ppx
HGF increases b-cell proliferation in adult transgenic
mice in basal conditions (4). Since islet c-Met is upreg-
ulated post-Ppx, we examined whether HGF adminis-
tration could further enhance b-cell regeneration after
Ppx. Daily HGF administration increased b-cell pro-
liferation compared with saline-treated controls 7 days
post-Ppx (Fig. 4A–F), suggesting that HGF could further
accelerate b-cell regeneration. Indeed, HGF increased
b-cell mass in Ppx mice at 7 days (P = 0.06) and 12 days
(P , 0.05) compared with saline-treated Ppx mice
Figure 3—Incomplete b-cell mass regeneration in PancMet KO mice after Ppx. A: Quantiﬁcation of b-cell mass in SH-operated (n = 5) and
Ppx (n = 7) WT and PancMet KO (n = 5 and n = 10, respectively) mice 28 days after surgery. Results are means6 SEM. P< 0.05 vs. sham-
operated WT or PancMet KO mice and Ppx WT mice. B: Intraperitoneal glucose tolerance test (3 g glucose/kg body wt) in sham-operated
(n = 5) and Ppx (n = 7) WT and PancMet KO (n = 5 and n = 10, respectively) mice 25 days after surgery. Results are means6 SEM. C: Area
under the curve (AUC) calculated from the intraperitoneal glucose tolerance test experiments in which sham-operated and Ppx WT and
PancMet KO mice 25 days after surgery were examined. Results are means6 SEM. P< 0.05 vs. sham-operated WT or PancMet KO mice
and Ppx WT mice. D: Quantitation of insulin secretion in islets isolated from WT (n = 6) and PancMet KO (n = 4) Ppx mice at 25 days
postsurgery and incubated with 2.8 and 22.2 mmol/L glucose for 30 min. Results are means 6 SEM. *P < 0.05 vs. islets at 2.8 mmol/L;
#P < 0.05 vs. Ppx WT islets at the same glucose concentration.
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(Fig. 4G and H). This highlights the therapeutic potential
of HGF for increasing b-cell regeneration in diabetes.
DISCUSSION
The current study provides the ﬁrst direct evidence that
endogenous pancreatic HGF/c-Met signaling is required
for b-cell regeneration in situations of diminished b-cell
mass. On one hand, c-Met absence in the mouse pancreas
diminishes b-cell replication leading to incomplete b-cell
mass expansion after Ppx and MLDS treatment (9). On
the other hand, HGF administration further enhances
mouse b-cell regeneration after Ppx. Therefore, activa-
tion of HGF/c-Met signaling is needed for full b-cell
regeneration and truly highlights this pathway as a
potential therapeutic target for b-cell regeneration in
diabetes.
The role of growth factors in the adaptive b-cell
proliferative response in situations of diminished b-cell
mass has been understudied. Multiple growth factors
have been shown to increase b-cell proliferation in vivo
in basal conditions; however, only GLP-1 has been shown
to be required for b-cell regeneration after Ppx (12).
GLP-1 receptor2/2 mice displayed markedly diminished
b-cell mass 5 weeks post-Ppx. Importantly, as in the
GLP-1 studies, mice with pancreatic c-Met deletion dis-
played decreased b-cell proliferation and incomplete
b-cell mass recovery after Ppx. This would suggest that at
least in mice, both GLP-1 and HGF are required for
complete b-cell regeneration after Ppx. It is important to
note that both HGF and GLP-1 activate protein kinase
C-z, and this activation is required for increasing pro-
liferation in rodent b-cells (17,18). It is important to
note that c-Met deletion in islets also led to decreased
GSIS and glucose intolerance 25 days post-Ppx, aspects
not present in PancMet KO mice in basal conditions (9).
Similarly, pregnant PancMet KO mice display incomplete
maternal b-cell expansion and defective GSIS (10). Taken
together, these observations suggest that c-Met de-
ﬁciency in pancreas is associated not only with in-
complete b-cell expansion in physiological and
pathological models but also with defective insulin
secretion.
Interestingly, c-Met–null islets did not display the
upregulation of cyclin D1 and D2 observed in WT mouse
islets after Ppx. D cyclins are essential for postnatal b-cell
growth, and their overexpression leads to increased b-cell
proliferation (19,20). Therefore, it is likely that the di-
minished levels of islet D cyclins in PancMet KO mice
might compromise the accelerated cell cycle progression
and regeneration after Ppx.
It has been suggested that b-cell regeneration, in the
face of immune destruction, occurs in patients with
recent-onset type 1 diabetes (21,22). To further assess the
regenerative role of HGF/c-Met signaling, we analyzed
b-cell replication in PancMet KO mice in a surrogate
model of islet inﬂammation with features of type 1 di-
abetes: the MLDS model (9). In this model, the enhanced
Figure 4—b-Cell proliferation in Ppx WT mice treated with saline
or HGF. A–C: Representative photomicrographs of pancreatic
sections from SH-operated saline (Sal)-treated (A) and Ppx saline-
treated (B) or HGF-treated (C) WT mice at 7 days postsurgery and
stained for insulin (green) and Ki67 (red). Arrows indicate Ki67-
positive b-cell nuclei. Magniﬁcation of the images is 3630. Mice
were treated daily with 20 mg/mouse HGF and 200 mg/mouse DS
in saline or an identical volume of saline for 7 days. D–G: Quan-
tiﬁcation of the percentage of Ki67-positive (D), BrdU-positive (E),
and pHH3-positive (F ) b-cells and b-cell mass (G) in SH-operated
saline-treated (n = 4) and Ppx saline-treated (n = 7) or HGF-treated
(n = 4) WT mice 7 days after surgery. H: b-Cell mass in mice
treated with HGF (n = 4) or saline (sham, n = 3; Ppx, n = 3) for 12
days as indicated above. Results are means 6 SEM. *P < 0.05 vs.
saline-injected SH-operated mice; #P < 0.05 vs. saline-injected
Ppx-operated mice.
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b-cell proliferation observed in WT mice was impaired in
c-Met–null islets, further conﬁrming that HGF/c-Met
signaling is essential for b-cell regeneration, even in
a setting with cytotoxic- and immune-mediated re-
duction of b-cells. Taken together, these and previous
studies indicate that although endogenous HGF/c-Met
signaling is dispensable for normal adult b-cell growth
in basal conditions, it is required for b-cell proliferation
in situations of diminished b-cell mass such as Ppx and
MLDS administration (current studies) and increased
metabolic demand such as pregnancy and obesity/insulin
resistance (10,23). This highlights HGF as a key growth
factor for b-cell proliferation and expansion in patho-
physiologic situations.
Since HGF/c-Met signaling is required for b-cell pro-
liferation after Ppx, islet c-Met is increased after Ppx, and
HGF is a mitogen for rodent b-cells (4), we wondered
whether HGF administration in vivo could lead to further
enhanced b-cell regeneration. Daily HGF administration
further accelerated the already high levels of b-cell pro-
liferation found in mice after Ppx. Importantly, this in-
crease in b-cell proliferation in HGF-treated Ppx mice led
to a further increase in b-cell mass compared with saline-
treated mice. This indicates that HGF could be used as
a regenerative factor for the treatment of diabetes.
Nevertheless, it is clear that unwanted proliferation of
non–b-cells might be a concern when administration of
growth factors/hormones is suggested as a potential
therapy for regenerative purposes. It is important to
note that circulating HGF levels are increased not only
in situations related to uncontrolled cell replication but
also in situations such as pregnancy (10,24) and obesity
(25). In addition, future approaches targeting speciﬁ-
cally the b-cell could further facilitate the use of acti-
vators of the HGF/c-Met signaling pathway without
potential worrisome uncontrolled proliferation of non-
b-cells.
In summary, these studies clearly indicate that HGF
is required for b-cell regeneration in situations of di-
minished b-cell mass. Importantly, HGF administration
can further increase b-cell regeneration in mice with di-
minished b-cell mass, highlighting HGF/c-met signaling
as a potential therapeutic target for enhancing b-cell
regeneration in diabetes.
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